FDA to Compounders: The GLP-1 Free Ride Is Over
With compounding pharmacies facing new scrutiny, the FDA signals a major shift in how off-brand GLP-1 medications will be regulated moving forward.
Latest Coverage
FDA and Novo Nordisk Go Nuclear on Compounded GLP-1s
The Hims & Hers lawsuit signals the end of an era for compounding operators as pharmaceutical giants aggressively defend their patents.
April 14, 2026 • 6 min readFDA Approves Foundayo: Eli Lilly's $36B Bet Against Oral Wegovy
The oral GLP-1 wars have officially begun as the FDA greenlights Eli Lilly's newest non-injectable weight loss treatment.
April 15, 2026 • 6 min read